Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Non Operating Income (2016 - 2026)

Cytosorbents filings provide 15 years of Non Operating Income readings, the most recent being -$1.1 million for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 81.03% to -$1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.1 million, a 203.23% increase, with the full-year FY2025 number at $6.1 million, up 203.22% from a year prior.
  • Non Operating Income hit -$1.1 million in Q4 2025 for Cytosorbents, down from -$709000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $5.6 million in Q2 2025 to a low of -$5.9 million in Q4 2024.
  • Median Non Operating Income over the past 5 years was -$716500.0 (2024), compared with a mean of -$145968.2.
  • The widest YoY moves for Non Operating Income: up 1034.68% in 2022, down 1120.28% in 2022.
  • Cytosorbents' Non Operating Income stood at -$481194.0 in 2021, then soared by 1034.68% to $4.5 million in 2022, then crashed by 40.13% to $2.7 million in 2023, then tumbled by 317.73% to -$5.9 million in 2024, then skyrocketed by 81.03% to -$1.1 million in 2025.
  • The last three reported values for Non Operating Income were -$1.1 million (Q4 2025), -$709000.0 (Q3 2025), and $5.6 million (Q2 2025) per Business Quant data.